Item Type | Name |
Academic Article
|
Prediction model for mortality after intracranial hemorrhage in patients with leukemia.
|
Academic Article
|
Can procalcitonin distinguish infectious fever from tumor-related fever in non-neutropenic cancer patients?
|
Academic Article
|
Pro-adrenomedullin as a novel biomarker for predicting infections and response to antimicrobials in febrile patients with hematologic malignancies.
|
Concept
|
Young Adult
|
Concept
|
Adult
|
Academic Article
|
Implications of discrepancy in morphologic diagnosis of myelodysplastic syndrome between referral and tertiary care centers.
|
Academic Article
|
Impact of comorbidities by ACE-27 in the revised-IPSS for patients with myelodysplastic syndromes.
|
Academic Article
|
BFR (bendamustine, fludarabine, and rituximab) allogeneic conditioning for chronic lymphocytic leukemia/lymphoma: reduced myelosuppression and GVHD.
|
Academic Article
|
The utility of proadrenomedullin and procalcitonin in comparison to C-reactive protein as predictors of sepsis and bloodstream infections in critically ill patients with cancer*.
|
Academic Article
|
Interferon alpha therapy for patients with essential thrombocythemia: final results of a phase II study initiated in 1986.
|
Academic Article
|
Adult acute megakaryocytic leukemia: an analysis of 37 patients treated at M.D. Anderson Cancer Center.
|
Academic Article
|
Activity of 9-nitro-camptothecin, an oral topoisomerase I inhibitor, in myelodysplastic syndrome and chronic myelomonocytic leukemia.
|
Academic Article
|
Phase 1 study of lonafarnib (SCH 66336) and imatinib mesylate in patients with chronic myeloid leukemia who have failed prior single-agent therapy with imatinib.
|
Academic Article
|
Results of dasatinib therapy in patients with early chronic-phase chronic myeloid leukemia.
|
Academic Article
|
Nilotinib as front-line treatment for patients with chronic myeloid leukemia in early chronic phase.
|
Academic Article
|
Outcome of patients with chronic myeloid leukemia with multiple ABL1 kinase domain mutations receiving tyrosine kinase inhibitor therapy.
|
Academic Article
|
Significance of thrombocytopenia in myelodysplastic syndromes: associations and prognostic implications.
|
Academic Article
|
Comparison of thalidomide and lenalidomide as therapy for myelofibrosis.
|
Academic Article
|
A randomized study of 2 dose levels of intravenous clofarabine in the treatment of patients with higher-risk myelodysplastic syndrome.
|
Academic Article
|
Phase II trial of vorinostat with idarubicin and cytarabine for patients with newly diagnosed acute myelogenous leukemia or myelodysplastic syndrome.
|
Academic Article
|
Monitoring and switching patterns of patients with chronic myeloid leukemia treated with imatinib in community settings: a chart review analysis.
|
Academic Article
|
Acute lymphoblastic leukemia in adults: encouraging developments on the way to higher cure rates.
|
Academic Article
|
Biological and clinical features of trisomy 21 in adult patients with acute myeloid leukemia.
|
Academic Article
|
Phase II trial of hyper CVAD and dasatinib in patients with relapsed Philadelphia chromosome positive acute lymphoblastic leukemia or blast phase chronic myeloid leukemia.
|
Academic Article
|
Gemtuzumab ozogamicin with fludarabine, cytarabine, and granulocyte colony stimulating factor (FLAG-GO) as front-line regimen in patients with core binding factor acute myelogenous leukemia.
|
Academic Article
|
Sudden blastic transformation in patients with chronic myeloid leukemia treated with imatinib mesylate.
|
Academic Article
|
Dasatinib.
|
Academic Article
|
Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors.
|
Academic Article
|
Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation following failure of imatinib mesylate therapy.
|
Academic Article
|
Kinase domain point mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia emerge after therapy with BCR-ABL kinase inhibitors.
|
Academic Article
|
Long-term follow-up of patients who experienced graft failure postallogeneic progenitor cell transplantation. Results of a single institution analysis.
|
Academic Article
|
Residual DNA methylation at remission is prognostic in adult Philadelphia chromosome-negative acute lymphocytic leukemia.
|
Academic Article
|
Treatment of myelofibrosis in younger patients: to transplant or not?
|
Academic Article
|
Nonmyeloablative allogeneic stem cell transplantation for chronic myelogenous leukemia in the imatinib era.
|
Academic Article
|
Current event-free survival after sequential tyrosine kinase inhibitor therapy for chronic myeloid leukemia.
|
Academic Article
|
A phase 1-2 study of a farnesyltransferase inhibitor, tipifarnib, combined with idarubicin and cytarabine for patients with newly diagnosed acute myeloid leukemia and high-risk myelodysplastic syndrome.
|
Academic Article
|
Impact of treatment end point definitions on perceived differences in long-term outcome with tyrosine kinase inhibitor therapy in chronic myeloid leukemia.
|
Academic Article
|
Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience.
|
Academic Article
|
Final results of the phase II study of rabbit anti-thymocyte globulin, ciclosporin, methylprednisone, and granulocyte colony-stimulating factor in patients with aplastic anaemia and myelodysplastic syndrome.
|
Academic Article
|
EUTOS score is not predictive for survival and outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors: a single institution experience.
|
Academic Article
|
Twice-daily fludarabine and cytarabine combination with or without gentuzumab ozogamicin is effective in patients with relapsed/refractory acute myeloid leukemia, high-risk myelodysplastic syndrome, and blast- phase chronic myeloid leukemia.
|
Academic Article
|
Prediction of outcomes in patients with Ph+ chronic myeloid leukemia in chronic phase treated with nilotinib after imatinib resistance/intolerance.
|
Academic Article
|
Allogeneic hematopoietic stem cell transplantation versus hypomethylating agents in patients with myelodysplastic syndrome: a retrospective case-control study.
|
Academic Article
|
Outcome after failure of second generation tyrosine kinase inhibitors treatment as first-line therapy for patients with chronic myeloid leukemia.
|
Academic Article
|
Clofarabine, idarubicin, and cytarabine (CIA) as frontline therapy for patients =60 years with newly diagnosed acute myeloid leukemia.
|
Academic Article
|
Similar outcome of patients with chronic myeloid leukemia treated with imatinib in or out of clinical trials.
|
Academic Article
|
Preclinical and early clinical evaluation of the oral AKT inhibitor, MK-2206, for the treatment of acute myelogenous leukemia.
|
Academic Article
|
Phase I study of cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, combined with cytarabine in patients with refractory leukemia.
|
Academic Article
|
Adult acute lymphoblastic leukemia.
|
Academic Article
|
Validation of the European Prognostic Index for younger adult patients with acute myeloid leukaemia in first relapse.
|
Academic Article
|
Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia.
|
Academic Article
|
Pretransplant positive positron emission tomography/gallium scans predict poor outcome in patients with recurrent/refractory Hodgkin lymphoma.
|
Academic Article
|
Novel tyrosine kinase inhibitor therapy before allogeneic stem cell transplantation in patients with chronic myeloid leukemia: no evidence for increased transplant-related toxicity.
|
Academic Article
|
Imatinib mesylate dose escalation is associated with durable responses in patients with chronic myeloid leukemia after cytogenetic failure on standard-dose imatinib therapy.
|
Academic Article
|
Low-dose azacitidine after allogeneic stem cell transplantation for acute leukemia.
|
Academic Article
|
Emerging therapy for the treatment of acute lymphoblastic leukemia.
|
Academic Article
|
Central nervous system prophylaxis in adults with acute lymphoblastic leukemia: current and emerging therapies.
|
Academic Article
|
Novel therapies for relapsed acute lymphoblastic leukemia.
|
Academic Article
|
Anthracycline dose intensification in adult acute lymphoblastic leukemia: lack of benefit in the context of the fractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimen.
|
Academic Article
|
Predictive factors for outcome and response in patients treated with second-generation tyrosine kinase inhibitors for chronic myeloid leukemia in chronic phase after imatinib failure.
|
Academic Article
|
Results of allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia patients who failed tyrosine kinase inhibitors after developing BCR-ABL1 kinase domain mutations.
|
Academic Article
|
Minimal cross-intolerance with nilotinib in patients with chronic myeloid leukemia in chronic or accelerated phase who are intolerant to imatinib.
|
Academic Article
|
The achievement of an early complete cytogenetic response is a major determinant for outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors.
|
Academic Article
|
The clinical significance of achieving different levels of cytogenetic response in patients with chronic phase chronic myeloid leukemia after failure to front-line therapy: is complete cytogenetic response the only desirable endpoint?
|
Academic Article
|
Characteristics of translocation (16;16)(p13;q22) acute myeloid leukemia.
|
Academic Article
|
Predicting survival of patients with hypocellular myelodysplastic syndrome: development of a disease-specific prognostic score system.
|
Academic Article
|
Analysis of outcomes in adolescents and young adults with chronic myelogenous leukemia treated with upfront tyrosine kinase inhibitor therapy.
|
Academic Article
|
Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study.
|
Academic Article
|
Phase I-II study of bendamustine in patients with acute leukemia and high risk myelodysplastic syndrome.
|
Academic Article
|
Treatment of adult acute lymphoblastic leukemia (ALL) with a focus on emerging investigational and targeted therapies.
|
Academic Article
|
Prognostic impact of RAS mutations in patients with myelodysplastic syndrome.
|
Academic Article
|
Early responses predict better outcomes in patients with newly diagnosed chronic myeloid leukemia: results with four tyrosine kinase inhibitor modalities.
|
Academic Article
|
Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia.
|
Academic Article
|
Assessment at 6 months may be warranted for patients with chronic myeloid leukemia with no major cytogenetic response at 3 months.
|
Academic Article
|
Significance of deeper molecular responses in patients with chronic myeloid leukemia in early chronic phase treated with tyrosine kinase inhibitors.
|
Academic Article
|
Decitabine can be safely reduced after achievement of best objective response in patients with myelodysplastic syndrome.
|
Academic Article
|
Allogeneic stem cell transplantation as initial salvage for patients with acute myeloid leukemia refractory to high-dose cytarabine-based induction chemotherapy.
|
Academic Article
|
Augmented Berlin-Frankfurt-M?nster therapy in adolescents and young adults (AYAs) with acute lymphoblastic leukemia (ALL).
|
Academic Article
|
Safety and clinical activity of 5-aza-2'-deoxycytidine (decitabine) with or without Hyper-CVAD in relapsed/refractory acute lymphocytic leukaemia.
|
Academic Article
|
2-Chlorodeoxyadenosine and cytarabine combination therapy for idiopathic hypereosinophilic syndrome.
|
Academic Article
|
Adult acute myeloid leukemia.
|
Academic Article
|
Neurologic complications associated with intrathecal liposomal cytarabine given prophylactically in combination with high-dose methotrexate and cytarabine to patients with acute lymphocytic leukemia.
|
Academic Article
|
Failure to achieve a complete hematologic response at the time of a major cytogenetic response with second-generation tyrosine kinase inhibitors is associated with a poor prognosis among patients with chronic myeloid leukemia in accelerated or blast phase.
|
Academic Article
|
Long-term outcome of patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors after imatinib failure is predicted by the in vitro sensitivity of BCR-ABL kinase domain mutations.
|
Academic Article
|
Defining the course and prognosis of adults with acute lymphocytic leukemia in first salvage after induction failure or short first remission duration.
|
Academic Article
|
Prognostic impact of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemia treated with nilotinib or dasatinib.
|
Academic Article
|
Phase I study of oral azacitidine in myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia.
|
Academic Article
|
Malignancies occurring during therapy with tyrosine kinase inhibitors (TKIs) for chronic myeloid leukemia (CML) and other hematologic malignancies.
|
Academic Article
|
FLT3 mutations in myelodysplastic syndrome and chronic myelomonocytic leukemia.
|
Academic Article
|
The achievement of a 3-month complete cytogenetic response to second-generation tyrosine kinase inhibitors predicts survival in patients with chronic phase chronic myeloid leukemia after imatinib failure.
|
Academic Article
|
Expectations of serious adverse events at the end of life of patients with acute myeloid leukemia who receive salvage therapy.
|
Academic Article
|
HCVAD plus imatinib or dasatinib in lymphoid blastic phase chronic myeloid leukemia.
|
Academic Article
|
Allogeneic stem cell transplantation for patients with chronic myeloid leukemia and acute lymphocytic leukemia after Bcr-Abl kinase mutation-related imatinib failure.
|
Academic Article
|
Chromosomal abnormalities in Philadelphia chromosome negative metaphases appearing during imatinib mesylate therapy in patients with newly diagnosed chronic myeloid leukemia in chronic phase.
|
Academic Article
|
Characteristics and outcome of chronic myeloid leukemia patients with F317L BCR-ABL kinase domain mutation after therapy with tyrosine kinase inhibitors.
|
Academic Article
|
Front-line therapy with second-generation tyrosine kinase inhibitors in patients with early chronic phase chronic myeloid leukemia: what is the optimal response?
|
Academic Article
|
Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls.
|
Academic Article
|
Clofarabine does not negatively impact the outcomes of patients with acute myeloid leukemia undergoing allogeneic stem cell transplantation.
|
Academic Article
|
Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION).
|
Academic Article
|
Patient-driven discontinuation of tyrosine kinase inhibitors: single institution experience.
|
Academic Article
|
Tyrosine kinase inhibitors as initial therapy for patients with chronic myeloid leukemia in accelerated phase.
|
Academic Article
|
Acute myeloid leukemia after myelodysplastic syndrome and failure of therapy with hypomethylating agents: an emerging entity with a poor prognosis.
|
Academic Article
|
Predicting outcomes in patients with chronic myeloid leukemia at any time during tyrosine kinase inhibitor therapy.
|
Academic Article
|
A phase I study of fludarabine, cytarabine, and oxaliplatin therapy in patients with relapsed or refractory acute myeloid leukemia.
|
Academic Article
|
Phase I trial of SAR103168, a novel multi-kinase inhibitor, in patients with refractory/relapsed acute leukemia or high-risk myelodysplastic syndrome.
|
Academic Article
|
A prognostic model of therapy-related myelodysplastic syndrome for predicting survival and transformation to acute myeloid leukemia.
|
Academic Article
|
Allogeneic stem cell transplant in patients with chronic lymphocytic leukemia with 17p deletion: consult-transplant versus consult- no-transplant analysis.
|
Academic Article
|
Myeloid neoplasms after breast cancer: "therapy-related" not an independent poor prognostic factor.
|
Academic Article
|
Results of phase 2 randomized study of low-dose decitabine with or without valproic acid in patients with myelodysplastic syndrome and acute myelogenous leukemia.
|
Academic Article
|
Flow cytometry immunophenotypic findings in chronic myelomonocytic leukemia and its utility in monitoring treatment response.
|
Academic Article
|
Phase II study of methotrexate, vincristine, pegylated-asparaginase, and dexamethasone (MOpAD) in patients with relapsed/refractory acute lymphoblastic leukemia.
|
Academic Article
|
Prognostic factors for outcome in patients with refractory and relapsed acute lymphocytic leukemia treated with inotuzumab ozogamicin, a CD22 monoclonal antibody.
|
Academic Article
|
Outcome of patients with low-risk and intermediate-1-risk myelodysplastic syndrome after hypomethylating agent failure: a report on behalf of the MDS Clinical Research Consortium.
|
Academic Article
|
Very high levels of lactate dehydrogenase at diagnosis predict central nervous system relapse in acute promyelocytic leukaemia.
|
Academic Article
|
A phase I/II study of the Janus kinase (JAK)1 and 2 inhibitor ruxolitinib in patients with relapsed or refractory acute myeloid leukemia.
|
Academic Article
|
Final report of a phase II study of imatinib mesylate with hyper-CVAD for the front-line treatment of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.
|
Academic Article
|
Phase I/II study of the hypoxia-activated prodrug PR104 in refractory/relapsed acute myeloid leukemia and acute lymphoblastic leukemia.
|
Academic Article
|
A Phase I/II Study of the mTOR Inhibitor Everolimus in Combination with HyperCVAD Chemotherapy in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia.
|
Academic Article
|
Age and Modified European LeukemiaNet Classification to Predict Transplant Outcomes: An Integrated Approach for Acute Myelogenous Leukemia Patients Undergoing Allogeneic Stem Cell Transplantation.
|
Academic Article
|
A phase I study of danusertib (PHA-739358) in adult patients with accelerated or blastic phase chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant or intolerant to imatinib and/or other second generation c-ABL therapy.
|
Academic Article
|
New insights into the pathophysiology and therapy of adult acute lymphoblastic leukemia.
|
Academic Article
|
Use of second- and third-generation tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia: an evolving treatment paradigm.
|
Academic Article
|
Ruxolitinib in combination with lenalidomide as therapy for patients with myelofibrosis.
|
Academic Article
|
Correlation of mutation profile and response in patients with myelofibrosis treated with ruxolitinib.
|
Academic Article
|
Jumping Translocations in Myeloid Malignancies Associated With Treatment Resistance and Poor Survival.
|
Academic Article
|
Pharmacokinetics of posaconazole prophylaxis of patients with acute myeloid leukemia.
|
Academic Article
|
The Effectiveness of Tyrosine Kinase Inhibitors and Molecular Monitoring Patterns in Newly Diagnosed Patients With Chronic Myeloid Leukemia in the Community Setting.
|
Academic Article
|
Estimated glomerular filtration rate changes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors.
|
Academic Article
|
Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study.
|
Academic Article
|
Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: a multicentre, randomised, dose-escalation phase 1 study.
|
Academic Article
|
Long-term follow-up of a phase 2 study of chemotherapy plus dasatinib for the initial treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.
|
Academic Article
|
Phase II trial of ponatinib in patients with chronic myeloid leukemia resistant to one previous tyrosine kinase inhibitor.
|
Academic Article
|
Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a single-centre, phase 2 study.
|
Academic Article
|
Conditional survival in patients with chronic myeloid leukemia in chronic phase in the era of tyrosine kinase inhibitors.
|
Academic Article
|
Detectable FLT3-ITD or RAS mutation at the time of transformation from MDS to AML predicts for very poor outcomes.
|
Academic Article
|
Increasing economic burden of tyrosine kinase inhibitor treatment failure by line of therapy in chronic myeloid leukemia.
|
Academic Article
|
Use of Real-World Claim Databases to Assess Prevalence of Comorbid Conditions Relevant to the Treatment of Chronic Myelogenous Leukemia Based on National Comprehensive Network Treatment Guidelines.
|
Academic Article
|
Sequential azacitidine and lenalidomide in patients with high-risk myelodysplastic syndromes and acute myeloid leukaemia: a single-arm, phase 1/2 study.
|
Academic Article
|
Long-term molecular and cytogenetic response and survival outcomes with imatinib 400 mg, imatinib 800 mg, dasatinib, and nilotinib in patients with chronic-phase chronic myeloid leukaemia: retrospective analysis of patient data from five clinical trials.
|
Academic Article
|
Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trials.
|
Academic Article
|
Minimal residual disease assessed by multi-parameter flow cytometry is highly prognostic in adult patients with acute lymphoblastic leukaemia.
|
Academic Article
|
Early T-cell precursor acute lymphoblastic leukemia/lymphoma (ETP-ALL/LBL) in adolescents and adults
|
Academic Article
|
Adult Acute Lymphoblastic Leukemia
|
Academic Article
|
Minimal residual disease assessed by multi-parameter flow cytometry is highly prognostic in adult patients with acute lymphoblastic leukaemia
|
Academic Article
|
A phase I study of danusertib (PHA-739358) in adult patients with accelerated or blastic phase chronic myeloid leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia resistant or intolerant to imatinib and/or other second generation c-ABL therapy
|
Academic Article
|
Treatment of adult acute lymphoblastic leukemia (ALL) with a focus on emerging investigational and targeted therapies
|
Academic Article
|
Prognostic significance of day 14 bone marrow evaluation in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia
|
Academic Article
|
Prognostic impact of pretreatment cytogenetics in adult Philadelphia chromosome-negative acute lymphoblastic leukemia in the era of minimal residual disease
|
Academic Article
|
Prognostic impact of persistent cytogenetic abnormalities at complete remission in adult patients with acute lymphoblastic leukemia
|
Academic Article
|
Evaluation of healthcare resource utilization and incremental economic burden of patients with chronic myeloid leukemia after disease progression to blast phase.
|
Academic Article
|
Novel Management Options for Adult Patients With Progressive Acute Lymphoblastic Leukemia: A Case-Study Compendium.
|
Academic Article
|
Ponatinib as first-line treatment for patients with chronic myeloid leukaemia in chronic phase: a phase 2 study.
|
Academic Article
|
Myelodysplastic syndromes following therapy with hypomethylating agents (HMAs): development of acute erythroleukemia may not influence assessment of treatment response.
|
Academic Article
|
Analysis of 2013 European LeukaemiaNet (ELN) responses in chronic phase CML across four frontline TKI modalities and impact on clinical outcomes.
|
Academic Article
|
Early T-cell precursor acute lymphoblastic leukemia/lymphoma (ETP-ALL/LBL) in adolescents and adults: a high-risk subtype.
|
Academic Article
|
Impact of BCR-ABL transcript type on outcome in patients with chronic-phase CML treated with tyrosine kinase inhibitors.
|
Academic Article
|
Clinical Safety and Efficacy of Nilotinib or Dasatinib in Patients With Newly Diagnosed Chronic-Phase Chronic Myelogenous Leukemia and Pre-Existing Liver and/or Renal Dysfunction.
|
Academic Article
|
Acute promyelocytic leukemia presented as a relapse of acute myeloid leukemia.
|
Academic Article
|
Interactions and relevance of blast percentage and treatment strategy among younger and older patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).
|
Academic Article
|
Prognostic impact of persistent cytogenetic abnormalities at complete remission in adult patients with acute lymphoblastic leukemia.
|
Academic Article
|
Clinical implications of TP53 mutations in myelodysplastic syndromes treated with hypomethylating agents.
|
Academic Article
|
Novel Approaches for the Interim Management of Relapsed/Refractory Acute Lymphocytic Leukemia: A Case-Study Compendium.
|
Academic Article
|
Outcomes of patients with myelodysplastic syndromes who achieve stable disease after treatment with hypomethylating agents.
|
Academic Article
|
Phase I study of evofosfamide, an investigational hypoxia-activated prodrug, in patients with advanced leukemia.
|
Academic Article
|
Multiparameter Analysis of Off-Target Effects of Dasatinib on Bone Homeostasis in Patients With Newly Diagnosed Chronic Myelogenous Leukemia.
|
Academic Article
|
Prognostic significance of day 14 bone marrow evaluation in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia.
|
Academic Article
|
A propensity score matching analysis of dasatinib and nilotinib as a frontline therapy for patients with chronic myeloid leukemia in chronic phase.
|
Academic Article
|
Activity of the oral mitogen-activated protein kinase kinase inhibitor trametinib in RAS-mutant relapsed or refractory myeloid malignancies.
|
Academic Article
|
The efficacy of current prognostic models in predicting outcome of patients with myelodysplastic syndromes at the time of hypomethylating agent failure.
|
Academic Article
|
Frontline therapy with high-dose imatinib versus second generation tyrosine kinase inhibitor in patients with chronic-phase chronic myeloid leukemia - a propensity score analysis.
|
Academic Article
|
Final results of a single institution experience with a pediatric-based regimen, the augmented Berlin-Frankfurt-M?nster, in adolescents and young adults with acute lymphoblastic leukemia, and comparison to the hyper-CVAD regimen.
|
Academic Article
|
Peripheral blood blast clearance is an independent prognostic factor for survival and response to acute myeloid leukemia induction chemotherapy.
|
Academic Article
|
Hyper-CVAD plus ponatinib versus hyper-CVAD plus dasatinib as frontline therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: A propensity score analysis.
|
Academic Article
|
Persistence of minimal residual disease assessed by multiparameter flow cytometry is highly prognostic in younger patients with acute myeloid leukemia.
|
Academic Article
|
Adult Acute Lymphoblastic Leukemia.
|
Academic Article
|
Impact of achievement of complete cytogenetic response on outcome in patients with myelodysplastic syndromes treated with hypomethylating agents.
|
Academic Article
|
Clinical characteristics of Philadelphia positive T-cell lymphoid leukemias-(De novo and blast phase CML).
|
Academic Article
|
Well-differentiated systemic mastocytosis showed excellent clinical response to imatinib in the absence of known molecular genetic abnormalities: A case report.
|
Academic Article
|
Phase 2 study of low-dose clofarabine plus cytarabine for patients with higher-risk myelodysplastic syndrome who have relapsed or are refractory to hypomethylating agents.
|
Academic Article
|
Significance of recurrence of minimal residual disease detected by multi-parameter flow cytometry in patients with acute lymphoblastic leukemia in morphological remission.
|
Academic Article
|
Relapse risk and survival in patients with FLT3 mutated acute myeloid leukemia undergoing stem cell transplantation.
|
Academic Article
|
Prognostic impact of pretreatment cytogenetics in adult Philadelphia chromosome-negative acute lymphoblastic leukemia in the era of minimal residual disease.
|
Academic Article
|
Ph-like acute lymphoblastic leukemia: a high-risk subtype in adults.
|
Academic Article
|
Frontline treatment of acute myeloid leukemia in adults.
|
Academic Article
|
Outcome of Patients With Therapy-Related Acute Myeloid Leukemia With or Without a History of Myelodysplasia.
|
Academic Article
|
Differential impact of minimal residual disease negativity according to the salvage status in patients with relapsed/refractory B-cell acute lymphoblastic leukemia.
|
Academic Article
|
Buparlisib, a PI3K inhibitor, demonstrates acceptable tolerability and preliminary activity in a phase I trial of patients with advanced leukemias.
|
Academic Article
|
Chronic myeloid leukemia among patients with a history of prior malignancies: A tale of dual survivorship.
|
Academic Article
|
Long-term outcome of acute promyelocytic leukemia treated with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab.
|
Academic Article
|
Poor outcomes associated with +der(22)t(9;22) and -9/9p in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia receiving chemotherapy plus a tyrosine kinase inhibitor.
|
Academic Article
|
Phase 2, randomized, double-blind study of pracinostat in combination with azacitidine in patients with untreated, higher-risk myelodysplastic syndromes.
|
Academic Article
|
Phase II trial of homoharringtonine with imatinib in chronic, accelerated, and blast phase chronic myeloid leukemia.
|
Academic Article
|
A phase 1 study of AMG 900, an orally administered pan-aurora kinase inhibitor, in adult patients with acute myeloid leukemia.
|
Academic Article
|
TP53 mutation does not confer a poor outcome in adult patients with acute lymphoblastic leukemia who are treated with frontline hyper-CVAD-based regimens.
|
Academic Article
|
A phase I study of moxetumomab pasudotox in adults with relapsed or refractory B-cell acute lymphoblastic leukaemia.
|
Academic Article
|
A phase I/II randomized trial of clofarabine or fludarabine added to idarubicin and cytarabine for adults with relapsed or refractory acute myeloid leukemia.
|
Academic Article
|
More than 1 TP53 abnormality is a dominant characteristic of pure erythroid leukemia.
|
Academic Article
|
Myeloid neoplasms with concurrent BCR-ABL1 and CBFB rearrangements: A series of 10 cases of a clinically aggressive neoplasm.
|
Academic Article
|
Treatment of acute lymphoblastic leukemia in older adults: now and the future.
|
Academic Article
|
Clinical characteristics and outcomes of previously untreated patients with adult onset T-acute lymphoblastic leukemia and T-lymphoblastic lymphoma with hyper-CVAD based regimens.
|
Academic Article
|
Outcomes of adults with relapsed or refractory Burkitt and high-grade B-cell leukemia/lymphoma.
|
Academic Article
|
Acute lymphoblastic leukemia in adolescents and young adults.
|
Academic Article
|
Clonal evolution and outcomes in myelofibrosis after ruxolitinib discontinuation.
|
Academic Article
|
New Tool for Monitoring Molecular Response in Patients With Chronic Myeloid Leukemia.
|
Academic Article
|
Hepatic adverse event profile of inotuzumab ozogamicin in adult patients with relapsed or refractory acute lymphoblastic leukaemia: results from the open-label, randomised, phase 3 INO-VATE study.
|
Academic Article
|
Prognostic factors and survival outcomes in patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era: Cohort study of 477 patients.
|
Academic Article
|
Salvage Chemoimmunotherapy With Inotuzumab Ozogamicin Combined With Mini-Hyper-CVD for Patients With Relapsed or Refractory Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: A Phase 2 Clinical Trial.
|
Academic Article
|
Co-occurrence of CRLF2-rearranged and Ph+ acute lymphoblastic leukemia: a report of four patients.
|
Academic Article
|
A phase II trial of ruxolitinib in combination with azacytidine in myelodysplastic syndrome/myeloproliferative neoplasms.
|
Academic Article
|
Treatment of adult acute lymphoblastic leukemia with inotuzumab ozogamicin.
|
Academic Article
|
Phase 1 dose escalation multicenter trial of pracinostat alone and in combination with azacitidine in patients with advanced hematologic malignancies.
|
Academic Article
|
Guadecitabine (SGI-110) in treatment-naive patients with acute myeloid leukaemia: phase 2 results from a multicentre, randomised, phase 1/2 trial.
|
Academic Article
|
Clinical outcomes in adult patients with aplastic anemia: A single institution experience.
|
Academic Article
|
Safety and Efficacy of Blinatumomab in Combination With a Tyrosine Kinase Inhibitor for the Treatment of Relapsed Philadelphia Chromosome-positive Leukemia.
|
Academic Article
|
Current paradigms in the management of Philadelphia chromosome positive acute lymphoblastic leukemia in adults.
|
Academic Article
|
Life after ponatinib failure: outcomes of chronic and accelerated phase CML patients who discontinued ponatinib in the salvage setting.
|
Academic Article
|
Outcome of patients with relapsed/refractory acute lymphoblastic leukemia after blinatumomab failure: No change in the level of CD19 expression.
|
Academic Article
|
A randomized phase 2 study of idarubicin and cytarabine with clofarabine or fludarabine in patients with newly diagnosed acute myeloid leukemia.
|
Academic Article
|
Randomized phase 2 study of low-dose decitabine vs low-dose azacitidine in lower-risk MDS and MDS/MPN.
|
Academic Article
|
A Phase II Study of Arginine Deiminase (ADI-PEG20) in Relapsed/Refractory or Poor-Risk Acute Myeloid Leukemia Patients.
|
Academic Article
|
Hyper-CVAD plus nelarabine in newly diagnosed adult T-cell acute lymphoblastic leukemia and T-lymphoblastic lymphoma.
|
Academic Article
|
Prognostic significance of additional chromosomal abnormalities at the time of diagnosis in patients with chronic myeloid leukemia treated with frontline tyrosine kinase inhibitors.
|
Academic Article
|
Ipilimumab plus Lenalidomide after Allogeneic and Autologous Stem Cell Transplantation for Patients with Lymphoid Malignancies.
|
Academic Article
|
Characteristics and outcome of chronic myeloid leukemia patients with E255K/V BCR-ABL kinase domain mutations.
|
Academic Article
|
Updated Results of Rituximab Pre- and Post-BEAM with or without 90Yttrium Ibritumomab Tiuxetan during Autologous Transplant for Diffuse Large B-cell Lymphoma.
|
Academic Article
|
Immunotherapy in adult acute lymphoblastic leukemia: the role of monoclonal antibodies.
|
Academic Article
|
Efficacy and safety analysis by age cohort of inotuzumab ozogamicin in patients with relapsed or refractory acute lymphoblastic leukemia enrolled in INO-VATE.
|
Academic Article
|
Chronic lymphoproliferative disorder of NK-cells: A single-institution review with emphasis on relative utility of multimodality diagnostic tools.
|
Academic Article
|
Philadelphia chromosome-positive acute lymphoblastic leukemia in adults: current treatments and future perspectives.
|
Academic Article
|
Blast phase chronic myelomonocytic leukemia: Mayo-MDACC collaborative study of 171 cases.
|
Academic Article
|
Final results of a phase 2, open-label study of indisulam, idarubicin, and cytarabine in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome.
|
Academic Article
|
Early results of lower dose dasatinib (50?mg daily) as frontline therapy for newly diagnosed chronic-phase chronic myeloid leukemia.
|
Academic Article
|
Dose, schedule, safety, and efficacy of guadecitabine in relapsed or refractory acute myeloid leukemia.
|
Academic Article
|
Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies.
|
Academic Article
|
Prediction for sustained deep molecular response of BCR-ABL1 levels in patients with chronic myeloid leukemia in chronic phase.
|
Academic Article
|
Chronic myeloid leukemia: 2018 update on diagnosis, therapy and monitoring.
|
Academic Article
|
Novel Therapies for Older Adults With Acute Lymphoblastic Leukemia.
|
Academic Article
|
Results of second salvage therapy in 673 adults with acute myelogenous leukemia treated at a single institution since 2000.
|
Academic Article
|
Clearance of Somatic Mutations at Remission and the Risk of Relapse in Acute Myeloid Leukemia.
|
Academic Article
|
Progress and Innovations in the Management of Adult Acute Lymphoblastic Leukemia.
|
Academic Article
|
A Pilot Phase II Study of Erlotinib for the Treatment of Patients with Relapsed/Refractory Acute Myeloid Leukemia.
|
Academic Article
|
Integrative genomic analysis of adult mixed phenotype acute leukemia delineates lineage associated molecular subtypes.
|
Academic Article
|
Validation of the 2017 revision of the WHO chronic myelomonocytic leukemia categories.
|
Academic Article
|
P53 protein overexpression in de novo acute myeloid leukemia patients with normal diploid karyotype correlates with FLT3 internal tandem duplication and worse relapse-free survival.
|
Academic Article
|
Impact of earlier versus later monitoring on disease progression and healthcare costs among patients with chronic myeloid leukemia in the United States.
|
Academic Article
|
Recommendations for the assessment and management of measurable residual disease in adults with acute lymphoblastic leukemia: A consensus of North American experts.
|
Academic Article
|
Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid Leukemia: A Nonrandomized, Open-Label, Phase II Study.
|
Academic Article
|
Prognosis of patients with intermediate risk IPSS-R myelodysplastic syndrome indicates variable outcomes and need for models beyond IPSS-R.
|
Academic Article
|
High-grade B-cell lymphomas with TdT expression: a diagnostic and classification dilemma.
|
Academic Article
|
Addition of eltrombopag to immunosuppressive therapy in patients with newly diagnosed aplastic anemia.
|
Academic Article
|
Chemoimmunotherapy with inotuzumab ozogamicin combined with mini-hyper-CVD, with or without blinatumomab, is highly effective in patients with Philadelphia chromosome-negative acute lymphoblastic leukemia in first salvage.
|
Academic Article
|
A prospective analysis of symptom burden for patients with chronic myeloid leukemia in chronic phase treated with frontline second- and third-generation tyrosine kinase inhibitors.
|
Academic Article
|
Bone marrow core biopsy in 508 consecutive patients with chronic myeloid leukemia: Assessment of potential value.
|
Academic Article
|
Serial minimal residual disease (MRD) monitoring during first-line FCR treatment for CLL may direct individualized therapeutic strategies.
|
Academic Article
|
Safety and tolerability of lurbinectedin (PM01183) in patients with acute myeloid leukemia and myelodysplastic syndrome.
|
Academic Article
|
Incorporating Immunotherapy Into the Treatment Strategies of B-Cell Adult Acute Lymphoblastic Leukemia: The Role of Blinatumomab and Inotuzumab Ozogamicin.
|
Academic Article
|
Validation of the 2017 European LeukemiaNet classification for acute myeloid leukemia with NPM1 and FLT3-internal tandem duplication genotypes.
|
Academic Article
|
Phase 1/2 study of DFP-10917 administered by continuous intravenous infusion in patients with recurrent or refractory acute myeloid leukemia.
|
Academic Article
|
The distribution of T-cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemia.
|
Academic Article
|
Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: long-term follow-up of a single-centre, phase 2 study.
|
Academic Article
|
Late relapse in acute myeloid leukemia (AML): clonal evolution or therapy-related leukemia?
|
Academic Article
|
Distinguishing thymoma from T-lymphoblastic leukaemia/lymphoma: a case-based evaluation.
|
Academic Article
|
Prognostic implications of cytogenetics in adults with acute lymphoblastic leukemia treated with inotuzumab ozogamicin.
|
Academic Article
|
Phase II Trial of MEK Inhibitor Binimetinib (MEK162) in RAS-mutant Acute Myeloid Leukemia.
|
Academic Article
|
CD123 expression patterns and selective targeting with a CD123-targeted antibody-drug conjugate (IMGN632) in acute lymphoblastic leukemia.
|
Academic Article
|
Tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia: a single-institution experience.
|
Academic Article
|
Allogeneic Transplantation after Myeloablative Rituximab/BEAM ? Bortezomib for Patients with Relapsed/Refractory Lymphoid Malignancies: 5-Year Follow-Up Results.
|
Academic Article
|
Incidence of second malignancies in patients with chronic myeloid leukemia in the era of tyrosine kinase inhibitors.
|
Academic Article
|
NPM1 mutant variant allele frequency correlates with leukemia burden but does not provide prognostic information in NPM1-mutated acute myeloid leukemia.
|
Academic Article
|
Risk Factors for Development of and Progression of Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome.
|
Academic Article
|
Clonal hematopoiesis of indeterminate potential-associated mutations and risk of comorbidities in patients with myelodysplastic syndrome.
|
Academic Article
|
Recent Advances in Adult Acute Lymphoblastic Leukemia.
|
Academic Article
|
Analysis of cardiovascular and arteriothrombotic adverse events in chronic-phase CML patients after frontline TKIs.
|
Academic Article
|
Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: Final report and long-term survival follow-up from the randomized, phase 3 INO-VATE study.
|
Academic Article
|
NPM1 mutations define a specific subgroup of MDS and MDS/MPN patients with favorable outcomes with intensive chemotherapy.
|
Academic Article
|
"Society of Hematologic Oncology (SOHO) State of the Art Updates and Next Questions"-Treatment of ALL.
|
Academic Article
|
L-carnitine and Vitamin B Complex for the Treatment of Pegasparaginase-induced Hyperbilirubinemia.
|
Academic Article
|
Development of a symptom assessment in patients with myelofibrosis: qualitative study findings.
|
Academic Article
|
Guadecitabine (SGI-110) in patients with intermediate or high-risk myelodysplastic syndromes: phase 2 results from a multicentre, open-label, randomised, phase 1/2 trial.
|
Academic Article
|
Early T precursor acute lymphoblastic leukaemia/lymphoma shows differential immunophenotypic characteristics including frequent CD33 expression and in vitro response to targeted CD33 therapy.
|
Academic Article
|
Outcomes of patients with chronic phase chronic myeloid leukemia (CML-CP) after discontinuation of frontline ponatinib therapy.
|
Academic Article
|
Ibrutinib and Venetoclax for First-Line Treatment of CLL.
|
Academic Article
|
Unrecognized fluid overload during induction therapy increases morbidity in patients with acute promyelocytic leukemia.
|
Academic Article
|
Novel monoclonal antibody-based treatment strategies in adults with acute lymphoblastic leukemia.
|
Academic Article
|
SOHO State of the Art Update and Next Questions: Advances in the Treatment of Adult Acute Lymphoblastic Leukemia.
|
Academic Article
|
Sorafenib plus intensive chemotherapy improves survival in patients with newly diagnosed, FLT3-internal tandem duplication mutation-positive acute myeloid leukemia.
|
Academic Article
|
Therapy Options in Treating Acute Lymphoblastic Leukemia in Adults.
|
Academic Article
|
Idarubicin, cytarabine, and nivolumab in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a single-arm, phase 2 study.
|
Academic Article
|
Transplantation in adults with relapsed/refractory acute lymphoblastic leukemia who are treated with blinatumomab from a phase 3 study.
|
Academic Article
|
Efficacy and safety of generic imatinib after switching from original imatinib in patients treated for chronic myeloid leukemia in the United States.
|
Academic Article
|
Long-term follow-up of lower dose dasatinib (50?mg daily) as frontline therapy in newly diagnosed chronic-phase chronic myeloid leukemia.
|
Academic Article
|
Philadelphia chromosome-positive acute lymphoblastic leukemia at first relapse in the era of tyrosine kinase inhibitors.
|
Academic Article
|
Haploidentical transplantation for acute myeloid leukemia patients with minimal/measurable residual disease at transplantation.
|
Academic Article
|
The early achievement of measurable residual disease negativity in the treatment of adults with Philadelphia-negative B-cell acute lymphoblastic leukemia is a strong predictor for survival.
|
Academic Article
|
The role of cladribine in acute myeloid leukemia: an old drug up to new tricks.
|
Academic Article
|
Impact of minimal residual disease status in patients with relapsed/refractory acute lymphoblastic leukemia treated with inotuzumab ozogamicin in the phase III INO-VATE trial.
|
Academic Article
|
Long-term results of frontline dasatinib in chronic myeloid leukemia.
|
Academic Article
|
Long-term results of a phase 2 trial of nilotinib 400?mg twice daily in newly diagnosed patients with chronic-phase chronic myeloid leukemia.
|
Academic Article
|
Genomic context and TP53 allele frequency define clinical outcomes in TP53-mutated myelodysplastic syndromes.
|
Academic Article
|
Clinical Experience With Venetoclax Combined With Chemotherapy for Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia.
|
Academic Article
|
Outcomes of acute myeloid leukemia with myelodysplasia related changes depend on diagnostic criteria and therapy.
|
Academic Article
|
A phase 1/2 study of ruxolitinib and decitabine in patients with post-myeloproliferative neoplasm acute myeloid leukemia.
|
Academic Article
|
Phase 2 study of hyper-CMAD with liposomal vincristine for patients with newly diagnosed acute lymphoblastic leukemia.
|
Academic Article
|
Posttransplantation cyclophosphamide improves transplantation outcomes in patients with AML/MDS who are treated with checkpoint inhibitors.
|
Academic Article
|
Venetoclax and BCR-ABL Tyrosine Kinase Inhibitor Combinations: Outcome in Patients with Philadelphia Chromosome-Positive Advanced Myeloid Leukemias.
|
Academic Article
|
Hypomethylating Agent Therapy in Myelodysplastic Syndromes With Chromosome 3 Abnormalities.
|
Academic Article
|
Ultra-accurate Duplex Sequencing for the assessment of pretreatment ABL1 kinase domain mutations in Ph+ ALL.
|
Academic Article
|
Outcome of adults with relapsed/refractory T-cell acute lymphoblastic leukemia or lymphoblastic lymphoma.
|
Academic Article
|
Evolving therapy of adult acute lymphoblastic leukemia: state-of-the-art treatment and future directions.
|
Academic Article
|
Hyper-CVAD regimen in combination with ofatumumab as frontline therapy for adults with Philadelphia chromosome-negative B-cell acute lymphoblastic leukaemia: a single-arm, phase 2 trial.
|
Academic Article
|
Genomic and Immunophenotypic Landscape of Aggressive NK-Cell Leukemia.
|
Academic Article
|
Phase I/II study of dasatinib in combination with decitabine in patients with accelerated or blast phase chronic myeloid leukemia.
|
Academic Article
|
Atypical cases of necrotizing sweet syndrome in patients with myelodysplastic syndrome and acute myeloid leukaemia.
|
Academic Article
|
Inotuzumab ozogamicin for relapsed/refractory acute lymphoblastic leukemia: outcomes by disease burden.
|
Academic Article
|
Concepts in immuno-oncology: tackling B cell malignancies with CD19-directed bispecific T cell engager therapies.
|
Academic Article
|
Germline DNMT3A mutation in familial acute myeloid leukaemia.
|
Academic Article
|
Intensive Versus Non-Intensive Approach to Adults with Ph+ ALL: An Intensive Approach Is Still Standard of Care.
|
Academic Article
|
Natural history of newly diagnosed myelodysplastic syndrome with isolated inv(3)/t(3;3).
|
Academic Article
|
Translocation t(1;19)(q23;p13) in adult acute lymphoblastic leukemia - a distinct subtype with favorable prognosis.
|
Academic Article
|
Outcomes with sequential FLT3-inhibitor-based therapies in patients with AML.
|
Academic Article
|
Clinical characteristics and outcomes in patients with acute myeloid leukemia with concurrent FLT3-ITD and IDH mutations.
|
Academic Article
|
CD123 Expression in Philadelphia Chromosome-like B Acute Lymphoblastic Leukemia/Lymphoma.
|
Academic Article
|
Discontinuation of Maintenance Tyrosine Kinase Inhibitors in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia outside of Transplant.
|
Academic Article
|
The LEukemia Artificial Intelligence Program (LEAP) in chronic myeloid leukemia in chronic phase: A model to improve patient outcomes.
|
Academic Article
|
The Hyper-CVAD Regimen is an Optimal Pediatric-inspired Regimen for Adolescents and Adults With Acute Lymphoblastic Leukemia.
|
Academic Article
|
GATA3 rs3824662A allele in B-cell acute lymphoblastic leukemia in adults, adolescents and young adults: association with CRLF2 rearrangement and poor prognosis.
|
Academic Article
|
Phase 2 study of lenalidomide maintenance for patients with high-risk acute myeloid leukemia in remission.
|
Academic Article
|
Triplet therapy with venetoclax, FLT3 inhibitor and decitabine for FLT3-mutated acute myeloid leukemia.
|
Academic Article
|
Venetoclax and Navitoclax in Combination with Chemotherapy in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma.
|
Academic Article
|
Clinical Outcomes of Patients With Chronic Myeloid Leukemia With Concurrent Core Binding Factor Rearrangement and Philadelphia Chromosome.
|
Academic Article
|
Outcome of T-cell acute lymphoblastic leukemia/lymphoma: Focus on near-ETP phenotype and differential impact of nelarabine.
|
Academic Article
|
Acute lymphoblastic leukemia: A population-based study of outcome in the United States based on the surveillance, epidemiology, and end results (SEER) database, 1980-2017.
|
Academic Article
|
Nivolumab maintenance in high-risk acute myeloid leukemia patients: a single-arm, open-label, phase II study.
|
Academic Article
|
Long-term follow-up of salvage therapy using a combination of inotuzumab ozogamicin and mini-hyper-CVD with or without blinatumomab in relapsed/refractory Philadelphia chromosome-negative acute lymphoblastic leukemia.
|
Academic Article
|
De novo acute myeloid leukemia: A population-based study of outcome in the United States based on the Surveillance, Epidemiology, and End Results (SEER) database, 1980 to 2017.
|
Academic Article
|
An effective chemotherapy-free regimen of ponatinib plus venetoclax for relapsed/refractory Philadelphia chromosome-positive acute lymphoblastic leukemia.
|
Academic Article
|
Activity of venetoclax-based therapy in chronic myelomonocytic leukemia.
|
Academic Article
|
FLT3 inhibitor based induction and allogeneic stem cell transplant in complete remission 1 improve outcomes in patients with newly diagnosed Acute Myeloid Leukemia with very low FLT3 allelic burden.
|
Academic Article
|
Inotuzumab ozogamicin with bosutinib for relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia or lymphoid blast phase of chronic myeloid leukemia.
|
Academic Article
|
Ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab (iFCG) regimen for chronic lymphocytic leukemia (CLL) with mutated IGHV and without TP53 aberrations.
|
Academic Article
|
Venetoclax Combined With FLAG-IDA Induction and Consolidation in Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia.
|
Academic Article
|
Central nervous system involvement in blastic plasmacytoid dendritic cell neoplasm.
|
Academic Article
|
Ibrutinib Plus Venetoclax for First-line Treatment of Chronic Lymphocytic Leukemia: A Nonrandomized Phase 2 Trial.
|
Academic Article
|
Impact of frontline treatment approach on outcomes of myeloid blast phase CML.
|
Academic Article
|
Hyper-CVAD plus ofatumumab versus hyper-CVAD plus rituximab as frontline therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: A propensity score analysis.
|
Academic Article
|
Impact of Philadelphia chromosome-like alterations on efficacy and safety of blinatumomab in adults with relapsed/refractory acute lymphoblastic leukemia: A post hoc analysis from the phase 3 TOWER study.
|
Academic Article
|
A phase 1b/2 study of azacitidine with PD-L1 antibody avelumab in relapsed/refractory acute myeloid leukemia.
|
Academic Article
|
Optimizing the treatment of acute lymphoblastic leukemia in younger and older adults: new drugs and evolving paradigms.
|
Academic Article
|
Phase II study of azacitidine with pembrolizumab in patients with intermediate-1 or higher-risk myelodysplastic syndrome.
|
Academic Article
|
Ten-day decitabine with venetoclax versus intensive chemotherapy in relapsed or refractory acute myeloid leukemia: A propensity score-matched analysis.
|
Academic Article
|
A phase 2a, single-arm, open-label study of tafasitamab, a humanized, Fc-modified, anti-CD19 antibody, in patients with relapsed/refractory B-precursor cell acute lymphoblastic leukemia.
|
Academic Article
|
Development of TP53 mutations over the course of therapy for acute myeloid leukemia.
|
Academic Article
|
Nine-Year Follow-up of Patients with Relapsed Follicular Lymphoma after Nonmyeloablative Allogeneic Stem Cell Transplant and Autologous Transplant.
|
Academic Article
|
Long-term outcome of hyper-CVAD-R for Burkitt leukemia/lymphoma and high-grade B-cell lymphoma: focus on CNS relapse.
|
Academic Article
|
Outcomes of acute lymphoblastic leukemia with KMT2A (MLL) rearrangement: the MD Anderson experience.
|
Academic Article
|
SOHO State of the Art Updates & Next Questions: Intensive and Non-Intensive Approaches for Adults With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia.
|
Academic Article
|
Predictors of outcomes in adults with acute myeloid leukemia and KMT2A rearrangements.
|
Academic Article
|
Prediction of early (4-week) mortality in acute myeloid leukemia with intensive chemotherapy.
|
Academic Article
|
Genetic correlates in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with Hyper-CVAD plus dasatinib or ponatinib.
|
Academic Article
|
Enhancer retargeting of CDX2 and UBTF::ATXN7L3 define a subtype of high-risk B-progenitor acute lymphoblastic leukemia.
|
Academic Article
|
Impact of frontline treatment approach on outcomes in patients with secondary AML with prior hypomethylating agent exposure.
|
Academic Article
|
Ponatinib for the treatment of adult patients with resistant or intolerant Chronic-Phase Chronic Myeloid Leukemia.
|
Academic Article
|
Urgent cytoreduction for newly diagnosed acute myeloid leukemia patients allows acquisition of pretreatment genomic data and enrollment on investigational clinical trials.
|
Academic Article
|
High-sensitivity next-generation sequencing MRD assessment in ALL identifies patients at very low risk of relapse.
|
Academic Article
|
Venetoclax combined with FLAG-IDA induction and consolidation in newly diagnosed acute myeloid leukemia.
|
Academic Article
|
Time to First Subsequent Salvage Therapy in Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia Treated With Inotuzumab Ozogamicin in the Phase III INO-VATE Trial.
|
Academic Article
|
Blinatumomab is associated with favorable outcomes in patients with B-cell lineage acute lymphoblastic leukemia and positive measurable residual disease at a threshold of 10-4 and higher.
|
Academic Article
|
Chronic myeloid leukemia: 2022 update on diagnosis, therapy, and monitoring.
|
Academic Article
|
Treatment of Adults With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia-From Intensive Chemotherapy Combinations to Chemotherapy-Free Regimens: A Review.
|
Academic Article
|
The role of allogeneic transplant for adult Ph+ ALL in CR1 with complete molecular remission: a retrospective analysis.
|
Academic Article
|
Hyper-CVAD-based regimens in adult patients with acute lymphoblastic leukemia.
|
Academic Article
|
Sequencing antigen-targeting antibodies and cellular therapies in adults with relapsed/refractory B-cell acute lymphoblastic leukemia.
|
Academic Article
|
Hyper-CVAD and sequential blinatumomab for newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: a single-arm, single-centre, phase 2 trial.
|
Academic Article
|
A phase 1 study to evaluate the safety, pharmacology, and feasibility of continuous infusion nelarabine in patients with relapsed and/or refractory lymphoid malignancies.
|
Academic Article
|
Frontline combination of ponatinib and hyper-CVAD in Philadelphia chromosome-positive acute lymphoblastic leukemia: 80-months follow-up results.
|
Academic Article
|
Management of acute lymphoblastic leukemia in older adults.
|
Academic Article
|
The emerging use of chemotherapy-free regimens in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia.
|
Academic Article
|
SOHO State of the Art Updates and Next Questions | Hyper-CVAD in 2022: Lessons Learned and New Approaches.
|
Academic Article
|
Early mortality in acute myeloid leukemia with KMT2A rearrangement is associated with high risk of bleeding and disseminated intravascular coagulation.
|
Academic Article
|
Outcomes of adult patients with relapsed/refractory CRLF2 rearranged B-cell acute lymphoblastic leukemia.
|
Academic Article
|
The evolution of acute lymphoblastic leukemia research and therapy at MD Anderson over four decades.
|
Academic Article
|
Chimeric antigen receptor T-cell therapy for adult B-cell acute lymphoblastic leukemia: state-of-the-(C)ART and the road ahead.
|
Academic Article
|
Immunophenotypic and genomic landscape of Richter transformation diffuse large B-cell lymphoma.
|
Academic Article
|
Impact of type of induction therapy on outcomes in older adults with AML after allogeneic stem cell transplantation.
|
Academic Article
|
Results of salvage therapy with mini-hyper-CVD and inotuzumab ozogamicin with or without blinatumomab in pre-B acute lymphoblastic leukemia.
|
Academic Article
|
Philadelphia-Like Genetic Rearrangements in Adults With B-Cell ALL: Refractoriness to Chemotherapy and Response to Tyrosine Kinase Inhibitor in ABL Class Rearrangements.
|
Academic Article
|
A Phase I study of Milademetan (DS3032b) in combination with low dose cytarabine with or without venetoclax in acute myeloid leukemia: Clinical safety, efficacy, and correlative analysis.
|
Academic Article
|
Phase 2 study of inotuzumab ozogamicin for measurable residual disease in acute lymphoblastic leukemia in remission.
|
Academic Article
|
Real-World Effectiveness of Dasatinib Versus Imatinib in Newly Diagnosed Patients With Chronic Myeloid Leukemia.
|
Academic Article
|
A phase 1/2 study of mini-hyper-CVD plus venetoclax in patients with relapsed/refractory acute lymphoblastic leukemia.
|
Academic Article
|
Oral decitabine plus cedazuridine and venetoclax in patients with higher-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: a single-centre, phase 1/2 study.
|
Academic Article
|
Low-Dose Decitabine versus Low-Dose Azacitidine in Lower-Risk MDS.
|
Academic Article
|
Single agent subcutaneous blinatumomab for advanced acute lymphoblastic leukemia.
|